Cited by 2,087Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

Open access

Miller, Brian C., Sen, Debattama R., Al Abosy, Rose, Bi, Kevin, Virkud, Yamini V., LaFleur, Martin W., Yates, Kathleen B., Lako, Ana, Felt, Kristen, Naik, Girish S., Manos, Michael, Gjini, Evisa, Kuchroo, Juhi R., Ishizuka, Jeffrey J., Collier, Jenna L., Griffin, Gabriel K., Maleri, Seth, Comstock, Dawn E., Weiss, Sarah A., Brown, Flavian D., Panda, Arpit, Zimmer, Margaret D., Manguso, Robert T., Hodi, F. Stephen, Rodig, Scott J., Sharpe, Arlene H., Haining, W. Nicholas·2019·Nature Immunology

DOI 10.1038/s41590-019-0312-6PMC PMC6673650

Open this paper in CoChat — free account

Abstract

T cell dysfunction is a hallmark of many cancers, but the basis for T cell dysfunction and the mechanisms by which antibody blockade of the inhibitory receptor PD-1 (anti-PD-1) reinvigorates T cells are not fully understood. Here we show that such therapy acts on a specific subpopulation of exhausted CD8+ tumor-infiltrating lymphocytes (TILs). Dysfunctional CD8+ TILs possess canonical epigenetic and transcriptional features of exhaustion that mirror those seen in chronic viral infection. Exhausted CD8+ TILs include a subpopulation of 'progenitor exhausted' cells that retain polyfunctionality, persist long term and differentiate into 'terminally exhausted' TILs. Consequently, progenitor exhausted CD8+ TILs are better able to control tumor growth than are terminally exhausted T cells. Progenitor exhausted TILs can respond to anti-PD-1 therapy, but terminally exhausted TILs cannot. Patients with melanoma who have a higher percentage of progenitor exhausted cells experience a longer duration of response to checkpoint-blockade therapy. Thus, approaches to expand the population of progenitor exhausted CD8+ T cells might be an important component of improving the response to checkpoint blockade.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41590-019-0312-6

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Spatial reconstruction of single-cell gene expression data
Satija, R., Farrell, J. A., Gennert, D., Schier, A. F., & Regev, A. (2015) · Nature Biotechnology · doi:10.1038/nbt.3192 · Cited by 7,055
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
T cell exhaustion
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Self-citation
Control of Viremia in Simian Immunodeficiency Virus Infection by CD8 + Lymphocytes
Schmitz, J. E., Kuroda, M. J., Santra, S., Sasseville, V. G., Simon, M. A., Lifton, M. A., Rácz, P., Tenner‐Racz, K., Dalesandro, M. R., Scallon, B. J., et al. (1999) · Science · doi:10.1126/science.283.5403.857 · Cited by 2,167
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Self-citation
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072

Show all 53 references

Sorted by citations

Items 301–400 of 1,002

Control of Lymphocyte Fate, Infection, and Tumor Immunity by TCF-1
Raghu, D., Xue, H., & Mielke, L. A. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.10.006 · Cited by 98
Patient-derived melanoma organoid models facilitate the assessment of immunotherapies
Ou, L., Liu, S., Wang, H., Guo, Y., Guan, L., Shen, L., Luo, R., Elder, D. E., Huang, A. C. C., Karakousis, G. C., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104614 · Cited by 97
Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy
Trefny, M. P., Kirchhammer, N., der Maur, P. A., Natoli, M., Schmid, D., Germann, M., Fernandez-Rodriguez, L., Herzig, P., Lötscher, J., Akrami, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35583-w · Cited by 98
Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights
Kumar, S., Singh, S. K., Rana, B., & Rana, A. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.002 · Cited by 101
The architectural design of CD8+ T cell responses in acute and chronic infection: Parallel structures with divergent fates
Chung, H. K., McDonald, B., & Kaech, S. M. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20201730 · Cited by 105
A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy
Ding, M., Fan, Y., Lv, Y., Liu, J., Yu, N., Kong, D., Sun, H., & Li, J. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.06.041 · Cited by 99
Cellular and molecular mechanisms of CD8(+) T cell differentiation, dysfunction and exhaustion
Verdon, D. J., Mulazzani, M., & Jenkins, M. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197357 · Cited by 98
CXCL10 chemokine regulates heterogeneity of the CD8+ T cell response and viral set point during chronic infection
Ozga, A. J., Chow, M. T., Lopes, M. E., Servis, R. L., Pilato, M. D., Dehio, P., Lian, J., Mempel, T. R., & Luster, A. D. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.002 · Cited by 96
The GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure
Wu, V. H., Yung, B. S., Faraji, F., Saddawi‐Konefka, R., Wang, Z., Wenzel, A. T., Song, M., Pagadala, M. S., Clubb, L. M., Chiou, J., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01529-7 · Cited by 101
Exosomal PD‐L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
Zhou, K., Guo, S., Li, F., Sun, Q., & Liang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.569219 · Cited by 99
SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment
O’Connell, P., Hyslop, S., Blake, M. K., Godbehere, S., Amalfitano, A., & Aldhamen, Y. A. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000300 · Cited by 97
An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity
Xu, Y., Carrascosa, L. C., Yeung, Y. A., Chu, M. L.-H., Yang, W., Djuretic, I. M., Pappas, D. C., Zeytounian, J. L., Ge, Z., de Ruiter, V., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0058 · Cited by 97
Extremely Differentiated T Cell Subsets Contribute to Tissue Deterioration During Aging
Soto‐Heredero, G., Heras, M. M. G. D. L., Escrig-Larena, J. I., & Mittelbrunn, M. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-064501 · Cited by 96
Radiation-induced amphiregulin drives tumour metastasis
Piffkó, A., Yang, K., Panda, A., Heide, J., Tesak, K., Wen, C., Zawieracz, K., Wang, L., Naccasha, E. Z., Bugno, J., et al. (2025) · Nature · doi:10.1038/s41586-025-08994-0 · Cited by 109
Self-citation
The T cell differentiation landscape is shaped by tumour mutations in lung cancer
Ghorani, E., Reading, J. L., Henry, J. Y., de Massy, M. R., Rosenthal, R., Turati, V. A., Joshi, K., Furness, A. J. S., Aïssa, A. B., Saini, S. K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0066-y · Cited by 95
BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia
Kong, W., Dimitri, A. J., Wenliang, W., Jung, I.-Y., Ott, C. J., Fasolino, M., Wang, Y., Kulikovskaya, I. M., Gupta, M., Yoder, T., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145459 · Cited by 99
TCF-1: a maverick in T cell development and function
Gounari, F., & Khazaie, K. (2022) · Nature Immunology · doi:10.1038/s41590-022-01194-2 · Cited by 95
Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia
Rutella, S., Vadakekolathu, J. N., Mazziotta, F., Reeder, S., Yau, T. O., Mukhopadhyay, R., Dickins, B., Altmann, H., Krämer, M., Knaus, H. A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159579 · Cited by 96
mTOR regulates T cell exhaustion and PD-1–targeted immunotherapy response during chronic viral infection
Ando, S., Perkins, C. M., Sajiki, Y., Chastain, C., Valanparambil, R. M., Wieland, A., Hudson, W. H., Hashimoto, M., Ramalingam, S. S., Freeman, G. J., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci160025 · Cited by 96
Regulation of CD8+ T memory and exhaustion by the mTOR signals
Chen, Y., Xu, Z., Sun, H., Ouyang, X., Han, Y., Yu, H., Wu, N., Xie, Y., & Su, B. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01064-3 · Cited by 101
In vitro modeling of CD8 + T cell exhaustion enables CRISPR screening to reveal a role for BHLHE40
Wu, J. E., Manne, S., Ngiow, S. F., Baxter, A. E., Huang, H., Freilich, E., Clark, M. L., Lee, J. H., Chen, Z., Khan, O., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.ade3369 · Cited by 101
Supervised discovery of interpretable gene programs from single-cell data
Kunes, R., Walle, T., Land, M., Nawy, T., & Pe’er, D. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01940-3 · Cited by 106
Role of TCF‐1 in differentiation, exhaustion, and memory of CD8 + T cells: A review
Zhang, J., Lyu, T., Cao, Y., & Feng, H. (2021) · The FASEB Journal · doi:10.1096/fj.202002566r · Cited by 109
Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity
Zhang, Z., Ren, C., Xiao, R., Ma, S., Liu, H., Dou, Y., Fan, Y., Wang, S., Zhan, P., Gao, C., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adp7302 · Cited by 94
Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL
Anand, P., Guillaumet-Adkins, A., Dimitrova, V., Yun, H., Drier, Y., Sotudeh, N., Rogers, A. J., Ouseph, M. M., Nair, M. S., Potdar, S. V., et al. (2020) · Blood · doi:10.1182/blood.2019004547 · Cited by 97
Ectopic Tcf1 expression instills a stem-like program in exhausted CD8+ T cells to enhance viral and tumor immunity
Shan, Q., Hu, S. S., Chen, X., Danahy, D. B., Badovinac, V. P., Zang, C., & Xue, H. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0436-5 · Cited by 95
Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
Zuazo, M., Arasanz, H., Bocanegra, A., Fernández, G., Chocarro, L., Vera, R., Kochan, G. T., & Escors, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.586907 · Cited by 97
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Zeidner, J. F., Vincent, B. G., Ivanova, A., Moore, D. T., McKinnon, K. P., Wilkinson, A. D., Mukhopadhyay, R., Mazziotta, F., Knaus, H. A., Foster, M. C., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0070 · Cited by 94
Decoding the multicellular ecosystem of vena caval tumor thrombus in clear cell renal cell carcinoma by single-cell RNA sequencing
Shi, Y. X., Zhang, Q., Bi, H., Lu, M., Tan, Y., Zou, D., Ge, L., Chen, Z., Liu, C., Ci, W., et al. (2022) · Genome biology · doi:10.1186/s13059-022-02651-9 · Cited by 94
BCL6 promotes a stem-like CD8 + T cell program in cancer via antagonizing BLIMP1
Sun, Q., Cai, D., Liu, D., Zhao, X., Li, R., Xu, W. M., Xie, B., Gou, M., Wei, K., Li, Y., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adh1306 · Cited by 94
Resident memory T cells form during persistent antigen exposure leading to allograft rejection
Abou‐Daya, K. I., Tieu, R., Zhao, D., Rammal, R., Sacirbegovic, F., Williams, A. L., Shlomchik, W. D., Oberbarnscheidt, M. H., & Lakkis, F. G. (2021) · Science Immunology · doi:10.1126/sciimmunol.abc8122 · Cited by 92
IFNγ signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells
Mazet, J. M., Mahale, J. N., Tong, O., Watson, R. A., Lechuga‐Vieco, A. V., Pirgova, G., Lau, V. W. C., Attar, M., Koneva, L. A., Sansom, S. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35948-9 · Cited by 99
Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer
Guo, X., Nie, H., Zhang, W., Li, J., Ge, J., Xie, B., Hu, W., Zhu, Y., Zhong, N., Zhang, X., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.001 · Cited by 100
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy
Bulliard, Y., Andersson, B. S., Baysal, M. A., Damiano, J. S., & Tsimberidou, A. M. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01504-7 · Cited by 98
PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15
Kim, K. H., Kim, H. K., Kim, H., Kim, C. G., Lee, H., Han, J. W., Choi, S. J., Jeong, S., Jeon, M., Kim, H., et al. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0427-6 · Cited by 90
Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses
Kidman, J., Principe, N., Watson, M. W., Lassmann, T., Holt, R. A., Nowak, A. K., Lesterhuis, W. J., Lake, R., & Chee, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.587014 · Cited by 94
TCF-1 regulates HIV-specific CD8+ T cell expansion capacity
Rutishauser, R. L., Deguit, C. D. T., Hiatt, J. B., Blaeschke, F., Roth, T. L., Wang, L., Raymond, K. A., Starke, C. E., Mudd, J. C., Chen, W., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.136648 · Cited by 93
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer
Gulhati, P., Schalck, A. P., Jiang, S., Shang, X., Wu, C., Hou, P., Ruiz, S. H., Soto, L. M. S., Parra, E. R., Ying, H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00500-z · Cited by 89
Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma
Burrack, A. L., Spartz, E. J., Raynor, J. F., Wang, I., Olson, M. A., & Stromnes, I. M. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.059 · Cited by 89
Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR–T-cell responses against ALL
Zheng, W., Wei, J., Zebley, C. C., Jones, L. L., Dhungana, Y., Wang, Y., Mavuluri, J., Long, L., Fan, Y., Youngblood, B., et al. (2021) · Blood · doi:10.1182/blood.2020009309 · Cited by 89
PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells
Lee, Y.-H., Lee, H. J., Kim, H. C., Lee, Y., Nam, S. K., Hupperetz, C., Ma, J. S. Y., Wang, X., Singer, O., Kim, W. S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.004 · Cited by 89
Decitabine priming increases anti–PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models
Li, X., Li, Y., Dong, L., Chang, Y., Zhang, X., Wang, C., Chen, M., Bo, X., Chen, H., Han, W., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165673 · Cited by 92
Tumor immunogenicity dictates reliance on TCF1 in CD8+ T cells for response to immunotherapy
Escobar, G., Tooley, K., Oliveras, J. P., Huang, L., Cheng, H., Bookstaver, M. L., Edwards, C., Froimchuk, E., Xue, C., Mangani, D., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.08.001 · Cited by 91
Hypoxia Supports Differentiation of Terminally Exhausted CD8 T Cells
Bannoud, N., Dalotto‐Moreno, T., Kindgard, L., García, P. A., Blidner, A. G., Mariño, K. V., Rabinovich, G. A., & Croci, D. O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660944 · Cited by 92
Hypoxia Reduction Sensitizes Refractory Cancers to Immunotherapy
Jayaprakash, P., Vignali, P., Delgoffe, G. M., & Curran, M. A. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-060619-022830 · Cited by 87
Simultaneous quantitative imaging of two PET radiotracers via the detection of positron–electron annihilation and prompt gamma emissions
Pratt, E. C., López-Montes, A., Volpe, A., Crowley, M. J. P., Carter, L. M., Mittal, V., Pillarsetty, N., Ponomarev, V., Udías, J. M., Grimm, J., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01060-y · Cited by 88
Exploiting temporal aspects of cancer immunotherapy
Zemek, R. M., Anagnostou, V., da Silva, I. P., Long, G. V., & Lesterhuis, W. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00699-2 · Cited by 96
CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy
Jin, H., Ko, M., Choi, D., Kim, J. H., Lee, D.-H., Kang, S.-H., Kim, I., Lee, H. J., Choi, E. K., Kim, K., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0877 · Cited by 85
Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia
Anderson, N. D., Birch, J., Accogli, T., Criado, I., Khabirova, E., Parks, C., Wood, Y., Young, M. D., Porter, T., Richardson, R., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02415-3 · Cited by 87
Resident memory T cells and cancer
Gavil, N. V., Cheng, K., & Masopust, D. (2024) · Immunity · doi:10.1016/j.immuni.2024.06.017 · Cited by 104
Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach
de Rodas, M. L., Villalba-Esparza, M., Sanmamed, M. F., Chen, L., Rimm, D. L., & Schalper, K. A. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00984-x · Cited by 98
Clonal lineage tracing reveals mechanisms skewing CD8+ T cell fate decisions in chronic infection
Kasmani, M. Y., Zander, R., Chung, H. K., Chen, Y., Khatun, A., Damo, M., Topchyan, P., Johnson, K. E., Levashova, D., Burns, R., et al. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20220679 · Cited by 87
Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8+ exhausted-like T cells
Li, S., Li, K., Wang, K., Yu, H., Wang, X., Shi, M., Liang, Z., Zhou, Y., Hu, Y., Li, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43462-1 · Cited by 89
CX3CR1–CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment
Yamauchi, T., Hoki, T., Oba, T., Saito, H., Attwood, K. M., Sabel, M. S., Chang, A. E., Odunsi, K. O., & Ito, F. (2020) · JCI Insight · doi:10.1172/jci.insight.133920 · Cited by 83
Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma
Ficial, M., Jegede, O. A., Sant’Angelo, M., Hou, Y., Flaifel, A., Pignon, J., Braun, D. A., Wind‐Rotolo, M., Sticco-Ivins, M. A., Catalano, P. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3084 · Cited by 86
Self-citation
Multi-Omics Approaches in Immunological Research
Chu, X., Zhang, B., Koeken, V. A. C. M., Gupta, M. K., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.668045 · Cited by 87
IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8+ T cells to overcome immunotherapy resistance in cancer
Bae, J., Liu, L., Moore, C., Hsu, E. J., Zhang, A., Ren, Z., Sun, Z., Wang, X., Zhu, J., Shen, J., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-01024-5 · Cited by 85
Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma
Gaglia, G., Burger, M. L., Ritch, C. C., Rammos, D., Dai, Y., Crossland, G. E., Tavana, S. Z., Warchol, S., Jaeger, A. M., Naranjo, S., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.015 · Cited by 84
The SWI/SNF chromatin remodeling complexes BAF and PBAF differentially regulate epigenetic transitions in exhausted CD8+ T cells
Baxter, A. E., Huang, H., Giles, J. R., Chen, Z., Wu, J. E., Drury, S., Tuite-Dalton, K. A., Park, S. L., Torres, L., Simone, B. W., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.05.008 · Cited by 83
Characteristics and anatomic location of PD-1 + TCF1 + stem-like CD8 T cells in chronic viral infection and cancer
Im, S. J., Obeng, R. C., Nasti, T. H., McManus, D. T., Kamphorst, A. O., Gunisetty, S., Prokhnevska, N., Carlisle, J. W., Yu, K., Sica, G., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221985120 · Cited by 88
Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis
Li, B., Elsten-Brown, J., Li, M., Zhu, E., Li, Z., Chen, Y., Kang, E., Ma, F., Chiang, J., Li, Y.-R., et al. (2025) · Cell · doi:10.1016/j.cell.2025.04.032 · Cited by 91
Regulators of CD8+ T cell exhaustion
Sun, Q., & Dong, C. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01221-x · Cited by 91
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells
Li, H., Liu, Z., Liu, L., Zhang, H., Han, C., Girard, L., Park, H., Zhang, A., Dong, C., Ye, J., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100554 · Cited by 102
Cellular and molecular waypoints along the path of T cell exhaustion
Lan, X., Zebley, C. C., & Youngblood, B. (2023) · Science Immunology · doi:10.1126/sciimmunol.adg3868 · Cited by 87
Metal-ion-chelating phenylalanine nanostructures reverse immune dysfunction and sensitize breast tumour to immune checkpoint blockade
Tan, M., Cao, G., Wang, R., Cheng, L., Huang, W., Yin, Y., Ma, H., Ho, S., Wang, Z., Zhu, M., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01758-3 · Cited by 95
Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma
Yang, Z., Tian, H., Chen, X., Li, B., Bai, G., Cai, Q., Xu, J., Guo, W., Wang, S., Peng, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52977-0 · Cited by 85
Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells
Yang, M., Zhang, S., Sun, L., Huang, L., Yu, J., Zhang, J.-H., Tian, Y., Han, C., & Ma, J. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02175-9 · Cited by 99
Landscape of Exhausted Virus-Specific CD8 T Cells in Chronic LCMV Infection
Sandu, I., Cerletti, D., Oetiker, N., Borsa, M., Wagen, F., Spadafora, I., Welten, S. P. M., Stolz, U., Oxenius, A., & Claassen, M. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108078 · Cited by 78
Shortwave-infrared-light-emitting probes for the in vivo tracking of cancer vaccines and the elicited immune responses
Ren, F., Wang, F., Baghdasaryan, A., Li, Y., Liu, H., Hsu, R., Wang, C., Li, J., Zhong, Y., Salazar, F. B., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01083-5 · Cited by 85
The Transcription Factor TCF1 in T Cell Differentiation and Aging
Kim, C., Jin, J., Weyand, C. M., & Goronzy, J. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186497 · Cited by 86
Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota
Fidelle, M., Yonekura, S., Picard, M., Cogdill, A. P., Hollebecque, A., Roberti, M. P., & Zitvogel, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.600886 · Cited by 87
Targeting monoamine oxidase A for T cell–based cancer immunotherapy
Wang, X., Li, B., Kim, K. G., Wang, Y.-C., Li, Z., Yu, J., Zeng, S., Ma, X., Choi, I. Y., Biase, S. D., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abh2383 · Cited by 82
Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection
Montanari, N. R., Ramírez, R., Aggarwal, A., van Buuren, N. J., Doukas, M., Moon, C., Turner, S., Diehl, L. J., Li, L., Debes, J. D., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.02.016 · Cited by 81
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
Wu, W., Chia, T., Lu, J., Li, X., Guan, J., Li, Y., Fu, F., Zhou, S., Feng, Y., Deng, J., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00612-0 · Cited by 84
Mass‐produced gram‐negative bacterial outer membrane vesicles activate cancer antigen‐specific stem‐like CD8 + T cells which enables an effective combination immunotherapy with anti‐PD‐1
Won, S., Lee, C., Bae, S., Lee, J., Choi, D., Kim, M., Song, S., Lee, J., Kim, E., Shin, H., et al. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12357 · Cited by 81
Architects of immunity: How dendritic cells shape CD8 + T cell fate in cancer
Bhandarkar, V., Dinter, T., & Spranger, S. (2025) · Science Immunology · doi:10.1126/sciimmunol.adf4726 · Cited by 88
Persistent STAT5 activation reprograms the epigenetic landscape in CD4 + T cells to drive polyfunctionality and antitumor immunity
Ding, Z., Shi, H., Aboelella, N. S., Fesenkova, K., Park, E.-J., Liu, Z., Pei, L., Li, J., McIndoe, R., Xu, H., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aba5962 · Cited by 82
PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens
Damo, M., Hornick, N. I., Venkat, A., William, I., Clulo, K., Venkatesan, S., He, J., Fagerberg, E., Loza, J. L., Kwok, D. W., et al. (2023) · Nature · doi:10.1038/s41586-023-06217-y · Cited by 86
Beyond T cell exhaustion: TIM-3 regulation of myeloid cells
Dixon, K. O., Lahore, G. F., & Kuchroo, V. K. (2024) · Science Immunology · doi:10.1126/sciimmunol.adf2223 · Cited by 87
IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Moynihan, K. D., Kumar, M. P., Sultan, H., Pappas, D. C., Park, T., Chin, S. M., Bessette, P. H., Lan, R. Y., Nguyen, H. C., Mathewson, N. D., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1266 · Cited by 79
Rapid in vitro generation of bona fide exhausted CD8+ T cells is accompanied by Tcf7 promotor methylation
Zhao, M., Kiernan, C. H., Stairiker, C. J., Hope, J. L., León, L. G., van Meurs, M., Brouwers-Haspels, I., Boers, R., Boers, J., Gribnau, J. H., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008555 · Cited by 81
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
Goswami, M., Gui, G., Dillon, L. W., Lindblad, K. E., Thompson, J., Valdez, J., Kim, D., Ghannam, J. Y., Oetjen, K. A., DeStefano, C. B., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003392 · Cited by 84
The diversity of CD8+ T cell dysfunction in cancer and viral infection
Galluzzi, L., Smith, K. N., Liston, A., & Garg, A. D. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01161-6 · Cited by 94
CXCR3-CXCL9: It’s All in the Tumor
Humblin, É., & Kamphorst, A. O. (2019) · Immunity · doi:10.1016/j.immuni.2019.05.013 · Cited by 75
Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy
Moussion, C., & Delamarre, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101848 · Cited by 82
Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma
Salié, H., Wischer, L., D’Alessio, A., Godbole, I., Suo, Y., Otto-Mora, P., Beck, J., Neumann, O., Stenzinger, A., Schirmacher, P., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-332837 · Cited by 78
Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy
Jeong, S., & Park, S. (2020) · Immune Network · doi:10.4110/in.2020.20.e3 · Cited by 78
PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy
Simon, S., Voillet, V., Vignard, V., Wu, Z., Dabrowski, C., Jouand, N., Beauvais, T., Khammari, A., Braudeau, C., Josien, R., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001631 · Cited by 79
Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion
Lamarche, C., Ward‐Hartstonge, K. A., Tian, M., Lin, D. T. S., Huang, Q. B., Brown, A., Edwards, K., Novakovsky, G., Qi, C. N., Kobor, M. S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2219086120 · Cited by 87
Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy
Dabas, P., & Danda, A. (2023) · Medical Oncology · doi:10.1007/s12032-023-02146-y · Cited by 86
Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities
Roider, T., Baertsch, M., Fitzgerald, D., Vöhringer, H. S., Brinkmann, B. J., Czernilofsky, F., Knoll, M., Cid, L. L., Mathioudaki, A., Faßbender, B., et al. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01358-2 · Cited by 81
Stepwise activities of mSWI/SNF family chromatin remodeling complexes direct T cell activation and exhaustion
Battistello, E., Hixon, K., Comstock, D. E., Collings, C. K., Chen, X., Rodriguez-Hernaez, J., Lee, S., Cervantes, K. S., Hinkley, M. M., Ntatsoulis, K., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.02.026 · Cited by 78
Self-citation
FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer
Guan, Y., Kraus, S. G., Quaney, M. J., Daniëls, M. A., Mitchem, J. B., & Teixeiro, E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00586 · Cited by 76
Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma
Kim, M., Jin, Z., Kolb, R. H., Borcherding, N. C., Chatzkel, J. A., Falzarano, S. M., & Zhang, W. (2021) · Cancers · doi:10.3390/cancers13225856 · Cited by 80
Efficient recovery of potent tumour-infiltrating lymphocytes through quantitative immunomagnetic cell sorting
Wang, Z., Ahmed, S. U., Labib, M., Wang, H., Hu, X., Wei, J., Yao, Y., Moffat, J., Sargent, E. H., & Kelley, S. O. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00820-y · Cited by 76
Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects
Cortellino, S., Raveane, A., Chiodoni, C., Delfanti, G., Pisati, F., Spagnolo, V., Visco, E., Fragale, G., Ferrante, F., Magni, S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111256 · Cited by 76
Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation
Wischnewski, V., Maas, R. R., Aruffo, P. G., Soukup, K., Galletti, G., Kornete, M., Galland, S., Fournier, N., Lilja, J., Wirapati, P., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00566-3 · Cited by 75
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer
Pillai, R., LeBoeuf, S. E., Hao, Y., New, C., Blum, J. L. E., Rashidfarrokhi, A., Huang, S. M., Bahamon, C., Wu, W., Karadal-Ferrena, B., et al. (2024) · Science Advances · doi:10.1126/sciadv.adm9859 · Cited by 81
An early precursor CD8+ T cell that adapts to acute or chronic viral infection
McManus, D. T., Valanparambil, R. M., Medina, C. B., Scharer, C. D., McGuire, D. J., Sobierajska, E., Hu, Y., Chang, D. Y., Wieland, A., Lee, J., et al. (2025) · Nature · doi:10.1038/s41586-024-08562-y · Cited by 76
Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma
Pinato, D. J., Fessas, P., Sapisochin, G., & Marron, T. U. (2021) · Hepatology · doi:10.1002/hep.31697 · Cited by 74

Authors: Miller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., Manos, M., Gjini, E., Kuchroo, J. R., Ishizuka, J. J., Collier, J. L., Griffin, G. K., Maleri, S., Comstock, D. E., Weiss, S. A., Brown, F. D., Panda, A., Zimmer, M. D., Manguso, R. T., Hodi, F. S., Rodig, S. J., Sharpe, A. H., & Haining, W. N.
Affiliations: Broad Institute (US)
Massachusetts General Hospital (US)
Dana-Farber Cancer Institute (US)
Brigham and Women's Hospital (US)
Corresponding author: Haining, W. Nicholas
ORCID: Miller, Brian C.
Sen, Debattama R.
Al Abosy, Rose
Bi, Kevin
Virkud, Yamini V.
LaFleur, Martin W.
Yates, Kathleen B.
Lako, Ana
Felt, Kristen
Naik, Girish S.
Manos, Michael
Gjini, Evisa
Kuchroo, Juhi R.
Ishizuka, Jeffrey J.
Collier, Jenna L.
Griffin, Gabriel K.
Comstock, Dawn E.
Weiss, Sarah A.
Zimmer, Margaret D.
Manguso, Robert T.
Hodi, F. Stephen
Rodig, Scott J.
Sharpe, Arlene H.
Haining, W. Nicholas
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2019-02-18
Volume: 20
Issue: 3
Pages: 326-336
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/s41590-019-0312-6
PMC: PMC6673650
OpenAlex: W2913558101
Cited by: 2,087
References: 53
Citations by year: 2026: 319 · 2025: 334 · 2024: 358 · 2023: 300 · 2022: 276 · 2021: 269 · 2020: 176 · 2019: 55
FWCI: 81.19
Type: journal article
Language: en
Update notices: correction (2019-10-03)
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (KL2TR002542)
National Heart, Lung, and Blood Institute (T32HL007627)
National Cancer Institute (T32CA207021, T32CA009172)
National Institute of General Medical Sciences (T32GM007753)
National Institute of Allergy and Infectious Diseases (R01AI115712, K23AI130408, U19AI133524, P01AI056299)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: T cell exhaustion, CD8+ T cells, PD-1, anti-PD-1 therapy, immune checkpoint blockade, tumor-infiltrating lymphocytes, melanoma, T cell polyfunctionality, chronic viral infection, tumor control
MeSH terms: Animals, Female, Humans, Lymphocytic Choriomeningitis, Lymphocytic choriomeningitis virus, Melanoma, Experimental, Mice, Inbred C57BL, Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Antibodies, Blocking, Mice, Congenic, Cell Line, Tumor, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks